Do analysts recommend BDTX or CGC?

Black Diamond Therapeutics presently has a consensus price target of $9.83, indicating a potential upside of 443.28%. Given Black Diamond Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Black Diamond Therapeutics is more favorable than Canopy Growth. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Black Diamond Therapeutics 1 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.73 Canopy Growth 1 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.17

Does the media prefer BDTX or CGC?

In the previous week, Canopy Growth had 1 more articles in the media than Black Diamond Therapeutics. MarketBeat recorded 4 mentions for Canopy Growth and 3 mentions for Black Diamond Therapeutics. Black Diamond Therapeutics' average media sentiment score of 1.47 beat Canopy Growth's score of 0.63 indicating that Black Diamond Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Black Diamond Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Canopy Growth 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is BDTX or EPRX more profitable?

Black Diamond Therapeutics' return on equity of -30.18% beat Eupraxia Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Black Diamond Therapeutics N/A -30.18% -23.91% Eupraxia Pharmaceuticals N/A -87.56% -51.20%

Does the media refer more to BDTX or SLN?

In the previous week, Silence Therapeutics had 1 more articles in the media than Black Diamond Therapeutics. MarketBeat recorded 4 mentions for Silence Therapeutics and 3 mentions for Black Diamond Therapeutics. Black Diamond Therapeutics' average media sentiment score of 1.47 beat Silence Therapeutics' score of 0.53 indicating that Black Diamond Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Black Diamond Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Silence Therapeutics 0 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer AUTL or BDTX?

In the previous week, Black Diamond Therapeutics had 2 more articles in the media than Autolus Therapeutics. MarketBeat recorded 3 mentions for Black Diamond Therapeutics and 1 mentions for Autolus Therapeutics. Black Diamond Therapeutics' average media sentiment score of 1.47 beat Autolus Therapeutics' score of 1.20 indicating that Black Diamond Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Autolus Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Black Diamond Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Black Diamond Therapeutics (BDTX) Competitors

$1.81 +0.02 (+1.12%)

Closing price 07/20/2026 04:00 PM Eastern

Extended Trading

$1.82 +0.01 (+0.50%)

As of 09:19 AM Eastern

Compare

BDTX vs. CGC, EOLS, EPRX, SLN, and AUTL

Should you buy Black Diamond Therapeutics stock or one of its competitors? MarketBeat compares Black Diamond Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Black Diamond Therapeutics include Canopy Growth (CGC), Evolus (EOLS), Eupraxia Pharmaceuticals (EPRX), Silence Therapeutics (SLN), and Autolus Therapeutics (AUTL). These companies are all part of the "pharmaceutical products" industry.

How does Black Diamond Therapeutics compare to Canopy Growth?

Black Diamond Therapeutics (NASDAQ:BDTX) and Canopy Growth (NASDAQ:CGC) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, valuation, earnings, analyst recommendations, media sentiment, risk and institutional ownership.

Black Diamond Therapeutics presently has a consensus price target of $9.83, indicating a potential upside of 443.28%. Given Black Diamond Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Black Diamond Therapeutics is more favorable than Canopy Growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Black Diamond Therapeutics	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.73
Canopy Growth	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17

95.5% of Black Diamond Therapeutics shares are owned by institutional investors. Comparatively, 3.3% of Canopy Growth shares are owned by institutional investors. 9.3% of Black Diamond Therapeutics shares are owned by insiders. Comparatively, 0.2% of Canopy Growth shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Canopy Growth had 1 more articles in the media than Black Diamond Therapeutics. MarketBeat recorded 4 mentions for Canopy Growth and 3 mentions for Black Diamond Therapeutics. Black Diamond Therapeutics' average media sentiment score of 1.47 beat Canopy Growth's score of 0.63 indicating that Black Diamond Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Black Diamond Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Canopy Growth	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Black Diamond Therapeutics has higher earnings, but lower revenue than Canopy Growth. Black Diamond Therapeutics is trading at a lower price-to-earnings ratio than Canopy Growth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Black Diamond Therapeutics	$70M	1.48	$22.37M	-$0.77	N/A
Canopy Growth	$251.01M	1.67	-$190.29M	-$0.59	N/A

Black Diamond Therapeutics has a beta of 3.25, meaning that its stock price is 225% more volatile than the broader market. Comparatively, Canopy Growth has a beta of 0.79, meaning that its stock price is 21% less volatile than the broader market.

Black Diamond Therapeutics has a net margin of 0.00% compared to Canopy Growth's net margin of -75.27%. Canopy Growth's return on equity of -26.95% beat Black Diamond Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Black Diamond Therapeutics	N/A	-30.18%	-23.91%
Canopy Growth	-75.27%	-26.95%	-17.20%

Summary

Black Diamond Therapeutics beats Canopy Growth on 10 of the 17 factors compared between the two stocks.

How does Black Diamond Therapeutics compare to Evolus?

Black Diamond Therapeutics (NASDAQ:BDTX) and Evolus (NASDAQ:EOLS) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, profitability, risk, earnings, dividends and valuation.

Black Diamond Therapeutics has higher earnings, but lower revenue than Evolus. Evolus is trading at a lower price-to-earnings ratio than Black Diamond Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Black Diamond Therapeutics	$70M	1.48	$22.37M	-$0.77	N/A
Evolus	$297.18M	1.23	-$51.64M	-$0.67	N/A

Black Diamond Therapeutics has a beta of 3.25, suggesting that its share price is 225% more volatile than the broader market. Comparatively, Evolus has a beta of 1.32, suggesting that its share price is 32% more volatile than the broader market.

Black Diamond Therapeutics presently has a consensus price target of $9.83, indicating a potential upside of 443.28%. Evolus has a consensus price target of $16.00, indicating a potential upside of 188.29%. Given Black Diamond Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Black Diamond Therapeutics is more favorable than Evolus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Black Diamond Therapeutics	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.73
Evolus	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Black Diamond Therapeutics has a net margin of 0.00% compared to Evolus' net margin of -14.39%. Evolus' return on equity of 0.00% beat Black Diamond Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Black Diamond Therapeutics	N/A	-30.18%	-23.91%
Evolus	-14.39%	N/A	-19.03%

In the previous week, Black Diamond Therapeutics had 3 more articles in the media than Evolus. MarketBeat recorded 3 mentions for Black Diamond Therapeutics and 0 mentions for Evolus. Black Diamond Therapeutics' average media sentiment score of 1.47 beat Evolus' score of 0.00 indicating that Black Diamond Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Black Diamond Therapeutics	Positive
Evolus	Neutral

95.5% of Black Diamond Therapeutics shares are owned by institutional investors. Comparatively, 90.7% of Evolus shares are owned by institutional investors. 9.3% of Black Diamond Therapeutics shares are owned by company insiders. Comparatively, 5.0% of Evolus shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Black Diamond Therapeutics beats Evolus on 13 of the 17 factors compared between the two stocks.

How does Black Diamond Therapeutics compare to Eupraxia Pharmaceuticals?

Black Diamond Therapeutics (NASDAQ:BDTX) and Eupraxia Pharmaceuticals (NASDAQ:EPRX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, institutional ownership, valuation, dividends, profitability and media sentiment.

In the previous week, Black Diamond Therapeutics had 2 more articles in the media than Eupraxia Pharmaceuticals. MarketBeat recorded 3 mentions for Black Diamond Therapeutics and 1 mentions for Eupraxia Pharmaceuticals. Black Diamond Therapeutics' average media sentiment score of 1.47 beat Eupraxia Pharmaceuticals' score of 0.46 indicating that Black Diamond Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Black Diamond Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Eupraxia Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Black Diamond Therapeutics has a beta of 3.25, meaning that its share price is 225% more volatile than the broader market. Comparatively, Eupraxia Pharmaceuticals has a beta of 1.05, meaning that its share price is 5% more volatile than the broader market.

Black Diamond Therapeutics' return on equity of -30.18% beat Eupraxia Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Black Diamond Therapeutics	N/A	-30.18%	-23.91%
Eupraxia Pharmaceuticals	N/A	-87.56%	-51.20%

Black Diamond Therapeutics has higher revenue and earnings than Eupraxia Pharmaceuticals. Eupraxia Pharmaceuticals is trading at a lower price-to-earnings ratio than Black Diamond Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Black Diamond Therapeutics	$70M	1.48	$22.37M	-$0.77	N/A
Eupraxia Pharmaceuticals	N/A	N/A	-$38.58M	-$1.05	N/A

95.5% of Black Diamond Therapeutics shares are held by institutional investors. 9.3% of Black Diamond Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Black Diamond Therapeutics currently has a consensus target price of $9.83, suggesting a potential upside of 443.28%. Eupraxia Pharmaceuticals has a consensus target price of $18.00, suggesting a potential upside of 188.46%. Given Black Diamond Therapeutics' higher probable upside, equities analysts plainly believe Black Diamond Therapeutics is more favorable than Eupraxia Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Black Diamond Therapeutics	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.73
Eupraxia Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89

Summary

Black Diamond Therapeutics beats Eupraxia Pharmaceuticals on 13 of the 15 factors compared between the two stocks.

How does Black Diamond Therapeutics compare to Silence Therapeutics?

Black Diamond Therapeutics (NASDAQ:BDTX) and Silence Therapeutics (NASDAQ:SLN) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, valuation, profitability, media sentiment and institutional ownership.

Black Diamond Therapeutics has higher revenue and earnings than Silence Therapeutics. Silence Therapeutics is trading at a lower price-to-earnings ratio than Black Diamond Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Black Diamond Therapeutics	$70M	1.48	$22.37M	-$0.77	N/A
Silence Therapeutics	$560K	884.91	-$88.61M	-$1.59	N/A

Black Diamond Therapeutics has a beta of 3.25, suggesting that its share price is 225% more volatile than the broader market. Comparatively, Silence Therapeutics has a beta of 1.38, suggesting that its share price is 38% more volatile than the broader market.

Black Diamond Therapeutics presently has a consensus price target of $9.83, indicating a potential upside of 443.28%. Silence Therapeutics has a consensus price target of $55.00, indicating a potential upside of 424.31%. Given Black Diamond Therapeutics' higher probable upside, equities research analysts clearly believe Black Diamond Therapeutics is more favorable than Silence Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Black Diamond Therapeutics	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.73
Silence Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

95.5% of Black Diamond Therapeutics shares are held by institutional investors. Comparatively, 98.7% of Silence Therapeutics shares are held by institutional investors. 9.3% of Black Diamond Therapeutics shares are held by company insiders. Comparatively, 3.0% of Silence Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Black Diamond Therapeutics has a net margin of 0.00% compared to Silence Therapeutics' net margin of -8,943.86%. Black Diamond Therapeutics' return on equity of -30.18% beat Silence Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Black Diamond Therapeutics	N/A	-30.18%	-23.91%
Silence Therapeutics	-8,943.86%	-105.34%	-52.79%

In the previous week, Silence Therapeutics had 1 more articles in the media than Black Diamond Therapeutics. MarketBeat recorded 4 mentions for Silence Therapeutics and 3 mentions for Black Diamond Therapeutics. Black Diamond Therapeutics' average media sentiment score of 1.47 beat Silence Therapeutics' score of 0.53 indicating that Black Diamond Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Black Diamond Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Silence Therapeutics	0 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Black Diamond Therapeutics beats Silence Therapeutics on 12 of the 16 factors compared between the two stocks.

How does Black Diamond Therapeutics compare to Autolus Therapeutics?

Autolus Therapeutics (NASDAQ:AUTL) and Black Diamond Therapeutics (NASDAQ:BDTX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, risk, profitability, analyst recommendations, earnings and institutional ownership.

Autolus Therapeutics has a beta of 2.04, suggesting that its stock price is 104% more volatile than the broader market. Comparatively, Black Diamond Therapeutics has a beta of 3.25, suggesting that its stock price is 225% more volatile than the broader market.

Black Diamond Therapeutics has lower revenue, but higher earnings than Autolus Therapeutics. Black Diamond Therapeutics is trading at a lower price-to-earnings ratio than Autolus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Autolus Therapeutics	$75.39M	4.94	-$287.53M	-$1.09	N/A
Black Diamond Therapeutics	$70M	1.48	$22.37M	-$0.77	N/A

72.8% of Autolus Therapeutics shares are owned by institutional investors. Comparatively, 95.5% of Black Diamond Therapeutics shares are owned by institutional investors. 25.7% of Autolus Therapeutics shares are owned by insiders. Comparatively, 9.3% of Black Diamond Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Black Diamond Therapeutics has a net margin of 0.00% compared to Autolus Therapeutics' net margin of -311.98%. Black Diamond Therapeutics' return on equity of -30.18% beat Autolus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Autolus Therapeutics	-311.98%	-128.59%	-46.25%
Black Diamond Therapeutics	N/A	-30.18%	-23.91%

In the previous week, Black Diamond Therapeutics had 2 more articles in the media than Autolus Therapeutics. MarketBeat recorded 3 mentions for Black Diamond Therapeutics and 1 mentions for Autolus Therapeutics. Black Diamond Therapeutics' average media sentiment score of 1.47 beat Autolus Therapeutics' score of 1.20 indicating that Black Diamond Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Autolus Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Black Diamond Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Autolus Therapeutics currently has a consensus price target of $8.75, indicating a potential upside of 525.00%. Black Diamond Therapeutics has a consensus price target of $9.83, indicating a potential upside of 443.28%. Given Autolus Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Autolus Therapeutics is more favorable than Black Diamond Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Autolus Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89
Black Diamond Therapeutics	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.73

Summary

Black Diamond Therapeutics beats Autolus Therapeutics on 10 of the 17 factors compared between the two stocks.

Get Black Diamond Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BDTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BDTX vs. The Competition

Export

Metric	Black Diamond Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$102.57M	$3.69B	$6.89B	$12.28B
Dividend Yield	N/A	2.16%	2.67%	9.39%
P/E Ratio	-2.35	20.49	27.07	23.95
Price / Sales	1.48	300.33	515.72	90.33
Price / Cash	3.39	60.31	26.68	47.25
Price / Book	0.92	7.92	10.62	6.14
Net Income	$22.37M	$23.81M	$3.60B	$331.74M
7 Day Performance	-2.69%	-1.09%	-1.26%	-1.82%
1 Month Performance	9.04%	2.56%	1.07%	-1.45%
1 Year Performance	-42.54%	42.16%	23.63%	16.32%

Black Diamond Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BDTX Black Diamond Therapeutics	4.1468 of 5 stars	$1.81 +1.1%	$9.83 +443.3%	-42.2%	$102.57M	$70M	N/A	90	News Coverage Positive News
CGC Canopy Growth	1.152 of 5 stars	$0.96 -1.2%	N/A	-14.3%	$435.50M	$251.01M	N/A	1,128	Positive News
EOLS Evolus	1.6617 of 5 stars	$6.52 -1.4%	$16.00 +145.4%	-39.7%	$435.30M	$297.18M	N/A	170
EPRX Eupraxia Pharmaceuticals	2.6981 of 5 stars	$6.43 -3.7%	$18.00 +179.9%	+18.0%	$434.33M	N/A	N/A	29
SLN Silence Therapeutics	3.6155 of 5 stars	$9.29 +2.2%	$55.00 +492.0%	+73.7%	$429.36M	$560K	N/A	100	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BDTX) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Black Diamond Therapeutics (BDTX) Competitors

BDTX vs. CGC, EOLS, EPRX, SLN, and AUTL

How does Black Diamond Therapeutics compare to Canopy Growth?

Summary

How does Black Diamond Therapeutics compare to Evolus?

Summary

How does Black Diamond Therapeutics compare to Eupraxia Pharmaceuticals?

Summary

How does Black Diamond Therapeutics compare to Silence Therapeutics?

Summary

How does Black Diamond Therapeutics compare to Autolus Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BDTX vs. The Competition

Black Diamond Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Black Diamond Therapeutics (BDTX) Competitors

BDTX vs. CGC, EOLS, EPRX, SLN, and AUTL

How does Black Diamond Therapeutics compare to Canopy Growth?

Do analysts recommend BDTX or CGC?

Do insiders and institutionals believe in BDTX or CGC?

Does the media prefer BDTX or CGC?

Which has higher valuation & earnings, BDTX or CGC?

Which has more volatility and risk, BDTX or CGC?

Is BDTX or CGC more profitable?

Summary

How does Black Diamond Therapeutics compare to Evolus?

Which has better valuation & earnings, BDTX or EOLS?

Which has more volatility and risk, BDTX or EOLS?

Do analysts prefer BDTX or EOLS?

Is BDTX or EOLS more profitable?

Does the media prefer BDTX or EOLS?

Do insiders and institutionals believe in BDTX or EOLS?

Summary

How does Black Diamond Therapeutics compare to Eupraxia Pharmaceuticals?

Does the media prefer BDTX or EPRX?

Which has more risk & volatility, BDTX or EPRX?

Is BDTX or EPRX more profitable?

Which has preferable valuation & earnings, BDTX or EPRX?

Do insiders and institutionals believe in BDTX or EPRX?

Do analysts recommend BDTX or EPRX?

Summary

How does Black Diamond Therapeutics compare to Silence Therapeutics?

Which has stronger valuation & earnings, BDTX or SLN?

Which has more volatility and risk, BDTX or SLN?

Do analysts recommend BDTX or SLN?

Do insiders and institutionals have more ownership in BDTX or SLN?

Is BDTX or SLN more profitable?

Does the media refer more to BDTX or SLN?

Summary

How does Black Diamond Therapeutics compare to Autolus Therapeutics?

Which has more risk & volatility, AUTL or BDTX?

Which has preferable earnings and valuation, AUTL or BDTX?

Do institutionals and insiders have more ownership in AUTL or BDTX?

Is AUTL or BDTX more profitable?

Does the media prefer AUTL or BDTX?

Do analysts rate AUTL or BDTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BDTX vs. The Competition

Black Diamond Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools